DiaSorin launches LIAISON® Biotrin Parvovirus B19 IgG and IgM assays (available outside the US only)

08/03/2010

DiaSorin S.p.A. has announced the successful development of 2 new assays for detection of antibodies to Parvovirus B19 on the LIAISON® instrument: LIAISON® Biotrin Parvovirus B19 IgG and IgM.
Parvovirus B19 is an erythrovirus that has been associated to a growing number of clinical presentations, the two most important being Fifth Disease in children and fetal complications during pregnancy. Observed in outbreaks, parvovirus B19 is highly contagious and presents children, especially in the age group 4-11 with fever, muscle pains, arthralgia and a characteristic facial rash. In pregnancy, infection of the fetus during the first 28 weeks of term, can lead to cardiac failure, spontaneous abortion, or fetal hydrops. It is estimated that every year, in a population such as that of the European Union, there are more than 1.2 million pregnant women who are at risk of infection. Screening for IgG antibodies to parvovirus B19 allows the pregnant woman to know whether she is immune to infection. In parallel, the detection of IgM antibodies will alert the clinician to a current parvovirus B19 infection.
DiaSorin has collaborated with Biotrin International (Dublin, Ireland) to transfer the very successful Biotrin ELISA parvovirus B19 antibody detection technology to its LIAISON® fully automated platform. Due to exclusive antigen expression system in baculovirus, and unique assay features such as the direct IgM capture system, Biotrin has been the reference assay and market leader in parvovirus B19 diagnostics for over 10 years. Laboratories and clinicians can now benefit from all the features of the Biotrin EIA kits, but with the added technological advantages of full automation on the LIAISON® instrument.
With the addition of the two new Parvovirus B19 assays to the LIAISON® menu, DiaSorin is now the first company to be able to offer a full panel for detection of materno-fetal (TORCH) infections on a fully automated platform.